

**UNITED STATES DISTRICT COURT
DISTRICT OF NEVADA**

In re: CV SCIENCES, INC.
SECURITIES LITIGATION

This Document Relates to: All Actions

Case No. 2:18-cv-01602-JAD-BNW

**DECLARATION OF KARI L. SCHMIDT REGARDING: (A) DISSEMINATION OF
NOTICE TO THE CLASS; (B) PUBLICATION OF THE SUMMARY NOTICE; AND (C)
REPORT ON REQUESTS FOR EXCLUSION AND OBJECTIONS RECEIVED**

I, KARI L. SCHMIDT, hereby declare under penalty of perjury as follows:

1. I am a Project Manager for Analytics Consulting, LLC (“Analytics”). I am over 21 years of age and am not a party to the Action. The following statements are based on my personal knowledge and, if called on to do so, I could and would testify competently thereto.

2. Pursuant to its Order Certifying Settlement Class and Preliminarily Approving Class Action Settlement and Related Notices dated March 9, 2022 (ECF No. 166, the “Preliminary Approval Order”), the Court approved the retention of Analytics as the Claims Administrator for the above-captioned action (the “Action”).¹ I submit this declaration to provide the Court with (a) proof of the mailing of the Court-approved Notice Packet, consisting of the Notice of Pendency and Proposed Settlement of Class Action (the “Notice”) and the Proof of Claim and Release (the “Proof of Claim”), (b) proof of the publication of the Summary Notice of Proposed Settlement of Class Action (the “Summary Notice”), and (c) to report on the requests for exclusion from the Class and objections received in connection with dissemination of the Notice Packet.

¹ Unless otherwise defined in this declaration, all capitalized terms have the meanings defined in the Preliminary Approval Order.

MAILING OF THE NOTICE PACKET

3. Pursuant to the Preliminary Approval Order, Analytics has disseminated the Notice Packet to potential Class Members and nominees. A copy of the Notice Packet is attached to this declaration as Exhibit A.

4. Analytics received information from CV Sciences' Non-Objecting Beneficial Owner ("NOBO") List, which contained the names and addresses of potential members of the Class. This information contained 35,832 unique names and addresses of potential Class Members. On March 30, 2022, Analytics caused the Notice Packet to be disseminated by first-class mail to those 35,832 potential Class Members.

5. As in most class actions of this nature, the large majority of potential Class Members are beneficial purchasers whose securities are held in "street name" – *i.e.*, the securities are purchased by brokerage firms, banks, institutions, and other third-party nominees in the name of the nominee, on behalf of the beneficial purchasers. To provide targeted notice to investors, Analytics consulted with The Depository Trust Company (the "DTC") to identify banks, brokers, and other nominees that held CV Sciences common stock during the class period. On April 11, 2022, Analytics caused the Notice Packet and cover letter to be mailed to 115 brokerage firms, banks, institutions, other third-party nominees, and third-party filers.

6. On April 11, 2022, Analytics distributed the Notice to all custodian banks and broker-dealers in the United States via the DTC's Legal Electronic Notification System.

7. The Notice Packet instructed those who, during the period between June 19, 2017 and August 20, 2018 at 1:21 P.M. EST, inclusive (the "Class Period"), purchased CV Sciences common stock, for the beneficial interest of any person or entity other than themselves, that they must, within 10 calendar days of receipt of the Notice Packet, either: (i) request sufficient copies of the Notice Packet to forward to all such beneficial owners (and then forward the Notice Packets

to the beneficial owners within 10 calendar days of receipt) or (ii) provide the names and addresses of such Persons to the Claims Administrator. *See* Ex. A at Page 13 (ECF No. 158-2 at Page 20).

8. Through the date of this Declaration, Analytics has mailed an additional 5,859 copies of the Notice Packet to potential members of the Class whose names and addresses were received from individuals, entities, or nominees requesting that the Notice Packet be mailed to such persons.

9. Through the date of this Declaration, a total of 41,806 Notice Packets have been disseminated to potential members of the Class or their nominees. In addition, Analytics has re-mailed 530 Notice Packets to persons whose original mailings were returned by the U.S. Postal Service (“USPS”) as undeliverable and for whom updated addresses were provided to Analytics by the USPS.

PUBLICATION OF THE SUMMARY NOTICE PACKET

10. Pursuant to the Preliminary Approval Order, Analytics caused the Summary Notice to be published in *Investor’s Business Daily* and to be transmitted over *PR Newswire* on April 11, 2022. Copies of the proof of publication of the Summary Notice in the *Investor’s Business Daily* and over the *PR Newswire* are attached to this declaration as Exhibits B and C, respectively.

WEBSITE

11. Beginning on March 30, 2022, Analytics established and continues to maintain a website dedicated to this Action (www.CVSciencesSecuritiesLitigation.com) to assist Class Members. The website address was set forth in the Notice Packet and the Summary Notice. The website lists the deadline for requesting exclusion from the Class and contains copies of: the Stipulation of Settlement (ECF No. 158), the Notice Packet, Summary Notice, and this Court’s Preliminary Approval Order. Analytics will continue operating, maintaining, and updating the case website as appropriate.

TOLL-FREE TELEPHONE LINE

12. Beginning on March 30, 2022, Analytics established and continues to maintain a toll-free telephone number for the Action, 1-866-645-2347. During business hours, callers to the toll-free telephone line can speak to a live operator regarding the status of the Action and/or obtain answers to questions they may have about the Notice Packet. After hours, callers are provided with the opportunity to leave a message requesting a return call.

REPORT ON OBJECTIONS AND REQUESTS FOR EXCLUSION

13. The Notice Packet informed potential Class Members that requests for exclusion from the Class were to be mailed to Analytics, so as to be *received* no later than July 1, 2022. As of the date of this Declaration, Analytics has received one (1) request for exclusion, attached as Exhibit D, from shareholders Jesse Miller and Christine Moondancer, which was postmarked on April 27, 2022. Their request for exclusion was accompanied by financial statements evidencing the shareholders' proof of purchase of CV Sciences common stock. Such documentation has been omitted from Exhibit D to protect Miller and Moondancer's privacy. However, the financial statements list shares of CV Sciences common stock purchased outside the Class Period, on August 28, 2018 and August 29, 2018, respectively. Absent eligible purchases within the Class Period, Miller and Moondancer do not meet the definition of Class Members. Accordingly, although one (1) request for exclusion was received, no requests for exclusion have been received from any person or entity that would have otherwise been an actual Class Member.

14. The Notice Packet informed potential Class Members that objections to the proposed settlement were to be submitted to the Court, with copies sent to Lead Counsel and Defendants' Counsel, so as to be *received* no later than July 1, 2022. Although not required to be sent to Analytics, in the course of our settlement administration work, Analytics sometimes also



receives copies of objections from Class Members. For the sake of completeness here, I note that as of the date of this Declaration, Analytics has received no objections.

I declare, under penalty of perjury under the laws of the United States of America, that the foregoing is true and correct to the best of my knowledge.

Executed on June 1, 2022.



Kari L. Schmidt



06/01/2022

EXHIBIT A

UNITED STATES DISTRICT COURT
DISTRICT OF NEVADA

In re: CV SCIENCES, INC.
SECURITIES LITIGATION

Case No. 2:18-cv-01602-JAD-BNW

This Document Relates to: All Actions

NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION

If you purchased the common stock of CV Sciences, Inc. (“CV Sciences” or the “Company”) in the United States or on the OTC between June 19, 2017 and August 20, 2018 at 1:21 p.m. EST, inclusive, and were damaged thereby, then you may be entitled to a payment from a class action settlement.¹

A federal court authorized this Notice. This is not a solicitation from a lawyer.

- This settlement notice (the “Notice”) relates to a securities class action brought by an investor who alleges that CV Sciences and certain of its officers and directors made misrepresentations and/or omissions of material fact in violation of the federal securities laws.
- On March 9, 2022, the Court preliminarily approved a settlement of this class action (the “Settlement”). This Settlement is with defendants CV Sciences, Michael Mona, Jr. (“Mona Jr.”), Joseph D. Dowling (“Dowling”), and Michael Mona, III (“Mona III”) (collectively, the “Defendants”). Defendants deny all allegations of misconduct. The two sides disagree on whether the investors could have won at trial, and if so, how much money they could have won.
- The Settlement will provide a \$712,500 Settlement Amount for the benefit of investors who purchased CV Sciences common stock in the United States or on the OTC between June 19, 2017 and August 20, 2018 at 1:21 p.m. EST, inclusive, and are alleged to have been damaged thereby.
- Attorneys for Lead Plaintiff (“Lead Counsel”) will ask the Court for 25% of the Settlement Fund and up to \$50,000 in reimbursement for expenses incurred in prosecuting this lawsuit. Lead Counsel also intends to ask the Court to grant Lead Plaintiff an award of up to \$12,000 for reasonable costs and expenses (including lost wages) directly relating to his representation of the class. If approved by the Court, these amounts (totaling approximately \$0.004 per damaged share) will be paid from the Settlement Fund.
- The estimated average recovery, after deducting attorneys’ fees and expenses and administrative costs² (if approved by the Court), is \$0.008 per share.
 - **Your legal rights are affected whether you act or do not act. Read this Notice carefully.**

¹ All capitalized terms not otherwise defined in this document shall have the meaning provided in the Stipulation of Settlement dated January 31, 2022 (the “Stipulation”).

² The estimated notice and claims administration costs for this Settlement, which shall be paid from the Settlement Fund, are \$46,924.39. The cost is only an estimate, however, as the administration has not fully commenced as of the date of this Notice. Based upon the estimate, the notice and administration costs per share would be approximately \$0.0009.

YOUR LEGAL RIGHTS AND OPTIONS IN THIS SETTLEMENT	
SUBMIT A CLAIM FORM BY JULY 15, 2022	The only way to get a payment.
EXCLUDE YOURSELF BY JULY 1, 2022	Get no payment. This is the only option that allows you to ever be part of any other lawsuit against CV Sciences and the other Released Parties (as defined below) about the Released Claims (as defined below).
OBJECT BY JULY 1, 2022	Write to the Court about why you do not like the Settlement, the proposed Plan of Allocation, or Lead Counsel's application for an award of attorneys' fees and payment of expenses, and/or an award of reasonable costs and expenses to Lead Plaintiff.
GO TO A HEARING ON JULY 22, 2022 AT 10:00 A.M	Ask to speak in Court about the Settlement at the Final Approval Hearing.
DO NOTHING	Get no payment. Give up rights.

- These rights and options – **and the deadlines to exercise them** – are explained in this notice.
- The Court in charge of this case still has to decide whether to approve the Settlement. Payments will be made if the Court approves the Settlement and after any appeal is resolved. Please be patient.

SUMMARY OF THE NOTICE

Statement of Lead Plaintiff's Recovery

Lead Plaintiff has entered into a proposed Settlement with Defendants that, if approved by the Court, will resolve this Action in its entirety. Pursuant to the proposed Settlement, a Settlement Fund consisting of \$712,500 in cash ("Settlement Amount"), plus any accrued interest or income earned thereon (the "Settlement Fund"), has been established. Based on Lead Plaintiff's consulting expert's analysis, it is estimated that if class members submit claims for 100% of CV Sciences' common stock entitled to participate in the Settlement, the estimated average recovery per share of common stock would be \$0.013 per share before deduction of Court-approved fees and expenses, and approximately \$0.008 per share after Court-approved fees and expenses are deducted. **These average recovery amounts are only estimates and an individual Class Member may recover more or less than these estimates.** As described more fully below in the Plan of Allocation beginning on page 14, an individual Class Member's actual recovery will depend on several factors, including: (a) the total number of claims submitted; (b) when the Class Member purchased his, her, or its shares of CV Sciences common stock; and (c) whether and when the Class Member sold his, her, or its shares of CV Sciences common stock.

Statement of Potential Outcome of the Case

The Settling Parties disagree about both liability and damages and do not agree on the damages that would be recoverable if Lead Plaintiff was to prevail on each claim asserted against Defendants. The issues on which the Settling Parties disagree include, for example: (a) whether the statements made or facts allegedly omitted were materially misleading, or otherwise actionable under the federal securities laws; (b) whether any allegedly misleading statements or omissions made by Defendants were made with the requisite level of intent or recklessness; (c) the causes of the loss in the value of the stock; and (d) the amount of alleged damages, if any, that could be recovered at trial.

Statement of Attorneys' Fees and Expenses Sought

With the exception of court-awarded attorneys' fees involved in filing a motion to compel against certain defendants, Lead Counsel has not received any payment for their services rendered or expenses incurred in conducting this Action on behalf of Lead Plaintiff and the Class. If the Settlement is approved by the Court, Lead Counsel will apply to the Court for attorneys' fees of 25% of the Settlement Fund and up to \$50,000 in reimbursement for expenses incurred in prosecuting this lawsuit. If approved by the Court, these amounts (totaling approximately \$0.004 per share) will be paid from the Settlement Fund.

Identification of Legal Representatives

Lead Plaintiff and the Class are represented by Faruqi & Faruqi, LLP, Court-appointed Lead Counsel and Muckleroy Lunt, LLC, Court-appointed Liaison Counsel. Any questions regarding the Settlement should be directed to Katherine Lenahan, Faruqi & Faruqi, LLP, 685 Third Avenue, 26th Floor, New York, NY 10017, (212) 983-9330, klenahan@faruqilaw.com.

Reasons for the Settlement

For Lead Plaintiff, the principal reason for the Settlement is the immediate benefit of a cash recovery to the Class. This benefit must be compared to the uncertainty of being able to prove the allegations in the operative complaint; the uncertainty of having a class of CV Sciences investors certified; the risk that the Court may grant, in whole or in part, some or all of the anticipated motions for summary judgment to be filed by Defendants; the attendant risks of litigation, especially in complex actions such as this, as well as the difficulties and delays inherent in such litigation (including any appeals).

For Defendants, who deny all allegations of wrongdoing or liability whatsoever and deny that any Class Members were damaged, the principal reasons for entering into the Settlement are to bring to an end the substantial burden, expense, uncertainty, and risk of further litigation.

BASIC INFORMATION

1. Why did I get this Notice?

This Notice is being sent to people who may have purchased CV Sciences common stock in the United States or on the OTC between June 19, 2017 and August 20, 2018 at 1:21 p.m. EST. This Notice is being sent out because, if you made such purchases, you have a right to know about the proposed Settlement of a class action lawsuit, and about all of your options, before the Court decides whether to approve the Settlement.

The purpose of this Notice is to provide you with a Proof of Claim and Release form (“Proof of Claim” or “Claim Form”) and information regarding the deadline to submit that form if you wish to receive a payment from the Settlement.

This Notice explains the lawsuit, the Settlement, your legal rights, what benefits are available, who is eligible for them, and how to get them.

The Court in charge of the case is the United States District Court for the District of Nevada, and the case is known as *In re CV Sciences, Inc. Securities Litigation*, Case No. 2:18-cv-01602-JAD-BNW (D. Nev.) (the “Action”).

2. What is a class action?

In a class action, one or more plaintiffs, called lead plaintiffs or class representatives, sue on behalf of people who have similar claims. The individuals and entities on whose behalf the class representative is suing are known as class members. One court resolves the issues in the case for all class members, except for those who choose to exclude themselves from the class if exclusion is permitted by applicable rules of procedure.

3. What is this lawsuit about?

This lawsuit is a putative class action alleging violations of the federal securities laws by Defendants.

The Court has appointed Richard Ina, as Trustee for the Ina Family Trust (“Lead Plaintiff”) to serve as Lead Plaintiff in the Action and has appointed the law firm of Faruqi & Faruqi, LLP to serve as Lead Counsel and Muckleroy Lunt, LLC to serve as Liaison Counsel on behalf of the Class.

This Action claims that CV Sciences’ public statements were materially misleading. The Action seeks money damages against Defendants for violations of the federal securities laws. Defendants deny any wrongdoing or liability whatsoever.

The first complaint was filed in this Action on August 24, 2018 against CV Sciences and certain of its officers and directors. Lead Plaintiff thereafter filed an Amended Securities Class Action Complaint (“AC”) on January 4, 2019 against Defendants. Subsequently, on March 5, 2021, Lead Plaintiff filed a Second Amended Securities Class Action Complaint (“SAC”) against Defendants. The SAC generally alleges that Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (“Exchange Act”), and Rule 10b-5 promulgated thereunder, by reason of material misrepresentations and omissions. Specifically, Lead Plaintiff alleges that Defendants made materially misleading statements and omissions during the Class Period concerning the Company’s business as alleged in the SAC. (*See, e.g.*, SAC ¶¶49-81). The Action further alleges that the prices of CV Sciences common stock were artificially inflated as a result of Defendants’ actions and that investors suffered injury as a result of the alleged inflation.

Defendants believe that discovery and further litigation would reveal that: (a) the challenged statements were not materially misleading or otherwise actionable under the federal securities laws, at the time they were made; (b) Defendants did not make such statements recklessly or with knowledge that they were misleading; (c) Lead Plaintiff will not be able to prevail on their causal theory related to the stock price decline; and (d) the value of Lead Plaintiff's alleged damages are not supported or are inflated. Defendants also believe that no class could be certified in this case. As such, Defendants believe they would ultimately prevail in this litigation. However, given the time and expense necessary to continue to pursue this Action, Defendants believe it is in their best interests to enter into the Settlement with Lead Plaintiff and the Class.

4. How and when was the Settlement reached?

On March 5, 2019, Defendants filed a motion to dismiss the AC. On May 3, 2019, Lead Plaintiff filed opposition, to which the Defendants replied. On December 10, 2019, the Court denied Defendants' motion to dismiss, sustaining Lead Plaintiff's Section 10(b) claims against Defendants and Lead Plaintiff's control person claims under Section 20(a) against Dowling, Mona Jr. and Mona III.

Thereafter, the parties began to engage in discovery, and Lead Plaintiff filed the SAC. On May 19, 2020, the USPTO issued United States Patent No. 10,653,639, entitled "Pharmaceutical Formulations Containing Cannabidiol and Nicotine for Treating Smokeless Tobacco Addition," which the Company claims formally grants CV Sciences patent protection for the product at issue in this action. During the discovery process, the parties met and conferred frequently over discovery issues. Lead Plaintiff filed two motions to compel discovery: the first against Mona Jr. and Mona III in October 2020, which was granted and denied in part, and the second against CV Sciences and Dowling in March 2021, which was denied as moot after the parties informed the Court of their intent to engage in settlement negotiations.

The Settling Parties met for a mediation on October 25, 2021, before a private mediator. The mediation was preceded by submission of mediation statements and exhibits. Lead Plaintiff reached an agreement-in-principle with Defendants regarding the Settlement at the conclusion of the mediation session. Thereafter, Lead Plaintiff and Defendants executed the Stipulation to formalize their agreement.

WHO IS IN THE SETTLEMENT

To see if you will get money from this Settlement, you first have to determine if you are a Class Member.

5. How do I know if I am part of the Settlement?

Subject to certain exceptions identified below, everyone who fits this description is a Class Member: all Persons who purchased the common stock of CV Sciences in the United States or on the OTC between June 19, 2017 and August 20, 2018 at 1:21 p.m. EST, inclusive, and were allegedly damaged thereby.

6. Are there exceptions to being included?

Yes. There are some individuals and entities that are excluded from the Class by definition. Excluded from the Class are: (a) Defendants; (b) the officers and directors of the Company at all relevant times; (c) members of any Defendant's immediate families; (d) any entity in which Defendants have or had a controlling interest or which is related to or affiliated with any of the Defendants; (e) the legal representatives, heirs, agents, successors or assigns of such excluded Persons; (f) Defendants' liability insurance carriers and any affiliates or subsidiaries thereof; (g) those who purchased CV Sciences common stock on foreign exchanges, in accordance with the United States Supreme Court's decision in *Morrison v. Nat'l Australia Bank Ltd.*, 561 U.S. 247, 267 (2010) ("[I]t is in our view only transactions in securities listed on domestic exchanges, and domestic transactions in other securities, to which §10(b) applies."); and (h) any Persons who exclude themselves by submitting a request for exclusion that is accepted by the Court.

7. What if I am still not sure if I am included?

If are still not sure whether you are included, you can ask for free help by calling 1-866-645-2347 or visiting www.CVSciencesSecuritiesLitigation.com. You can also fill out and return the Proof of Claim form described on page 5, in question 9, to see if you qualify.

THE SETTLEMENT BENEFITS — WHAT YOU GET

8. What does the Settlement provide?

In exchange for the Settlement and release of the Released Claims against the Released Parties, Defendants have agreed to create a \$712,500 fund. After deductions for Court-awarded attorneys' fees, interest, and expenses, settlement administration

costs, and any applicable Taxes, the balance of the fund (the “Net Settlement Fund”) will be distributed *pro rata* pursuant to the “Plan of Allocation” among all Class Members who send in valid and timely Proof of Claim forms.

The Plan of Allocation, which is subject to Court approval, is discussed in more detail on pages 9-12 of this Notice.

9. How can I get a payment? When would I get my payment?

To qualify for a payment, you must submit a timely and valid Proof of Claim form with supporting documents. A Proof of Claim form is being circulated with this Notice. You may also get a Proof of Claim form on the Internet at www.CVSciencesSecuritiesLitigation.com. Read the instructions carefully, fill out the Proof of Claim form, include all the documents the form asks for, sign it, and either mail it to the Claims Administrator or submit it through email at Info@CVSciencesSecuritiesLitigation.com, such that your claim is postmarked (or submitted if sent via email) no later than July 15, 2022.

If you have large numbers of transactions, you may request, or may be requested to, submit information regarding your transactions in electronic files. If you wish to submit your transaction data electronically, you must contact the Claims Administrator at Info@CVSciencesSecuritiesLitigation.com or visit their website at www.CVSciencesSecuritiesLitigation.com to obtain the required file layout. You must still timely submit a manually signed Proof of Claim form by mail or email as specified above.

No electronic files will be considered to have been properly submitted unless the Claims Administrator issues to the claimant a written acknowledgement of receipt and acceptance of electronically submitted data. All claimants MUST timely submit a signed Proof of Claim form to be potentially eligible for a payment from this settlement.

The Court will hold a Final Approval Hearing on July 22, 2022 at 10:00 a.m., to decide whether to approve the Settlement. If the Court approves the Settlement, there may be appeals after that. It is always uncertain how and when these appeals ultimately will be resolved, and resolving them can take time, perhaps more than a year. It also takes time for all the Proof of Claim forms to be processed. Please be patient.

10. What am I giving up to get a payment or stay in the Class?

Unless you exclude yourself, you are staying in the Class, and that means that, upon the “Effective Date,” you will release all “Released Claims” (as defined below) against the “Released Parties” (as defined below).

“Released Claims” means all known or unknown claims that both: (a) arise out of, are based upon, or relate in any way to any of the allegations, acts, transactions, facts, events, matters, occurrences, statements, representations, misrepresentations or omissions involved, set forth, alleged or referred to, in this Action, or which could have been alleged in this Action; and (b) arise out of, are based upon, or relate in any way to the purchase of the common stock of CV Sciences in the United States or on the OTC during the Class Period. Released Claims do not include (i) any claims relating to the enforcement of the settlement or (ii) any Excluded Claims. “Released Claims” includes “Unknown Claims” as defined below.

“Excluded Claims” means the (i) derivative claims brought on behalf of CV Sciences, including *Depoti v. Dowling, et al.*, Docket No. A-18-782513-C (Nev. Dist. Ct. Oct. 10, 2018); *Francis v. Mona, Jr., et al.*, No. 2:18-cv-02284 (D. Nev. Nov. 30, 2018); *Tarangelo v. Mona, Jr., et al.*, Docket No. A-19-789153-B (Nev. Dist. Ct. Feb. 11, 2019); *Radcliffe v. Joseph Dowling, et al.*, Docket No. A-19-794377-B (Nev. Dist. Ct. May 7, 2019); *Berry v. Dowling, et al.*, Docket No. 3:20-cv-01072 (S.D. Cal. Jun. 11, 2020); *Menna v. Dowling, et al.*, Docket No. 37-2021-00019613-CU-SL-CTL (Cal. Super. Ct. Apr. 22, 2021), and any similar claims that may be filed or consolidated therewith; or (ii) any claims relating to the enforcement of the settlement.

“Related Parties” means each of Defendants’ predecessors, successors, parent corporations, sister corporations, subsidiaries, affiliates, assigns, assignors, divisions, joint ventures, heirs, legatees, executors, administrators, estates, receivers and trustees, settlors, beneficiaries, officers, directors, shareholders, employees, agents, consultants, contractors, auditors, partners, insurers, reinsurers, representatives, attorneys, legal representatives, and all persons acting by, through, under or in concert with them or any of them.

“Released Parties” means each and all of the Defendants and their respective Related Parties.

“Settled Defendants’ Claims” means all known or unknown claims, demands, losses, rights, and causes of action of any nature whatsoever, that have been or could have been asserted in the Action or any forum by the Released Parties or any of them against Lead Plaintiff, Class Members, and Plaintiff’s Counsel, which arise out of or relate in any way to the institution, prosecution, assertion, settlement, or resolution of the Action (except for claims to enforce the settlement). “Settled Defendants’ Claims” includes “Unknown Claims” as defined below.

“Unknown Claims” means: (a) any and all Released Claims that Lead Plaintiff or any Class Member does not know or suspect to exist in his, her, their or its favor at the time of the release of the Released Parties which, if known by him, her, them or it,

might have affected his, her, their or its settlement with and release of the Released Parties, or might have affected his, her, their or its decision(s) with respect to the settlement, including the decision to object to the terms of the settlement or to exclude himself, herself, themselves or itself from the settlement Class; and (b) any Settled Defendants' Claims that any Released Party does not know or suspect to exist in his, her, their or its favor at the time of the release of the Lead Plaintiff, Class Members, and Plaintiff's Counsel, which, if known by him, her, them or it, might have affected his, her, their or its decision(s) with respect to the settlement with and release of the Lead Plaintiff, Class Members, and Plaintiff's Counsel, or might have affected his, her, their or its decision(s) with respect to the settlement. With respect to any and all Released Claims and Settled Defendants' Claims, the Settling Parties stipulate and agree that, upon the Effective Date, Lead Plaintiff and Defendants shall expressly waive, and each of the Class Members shall be deemed to have, and by operation of the Judgment shall have, expressly waived any and all provisions, rights, and benefits conferred by California Civil Code §1542 and any law of any state or territory of the United States, or principle of common law, which is similar, comparable, or equivalent to California Civil Code §1542, which provides:

A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.

Lead Plaintiff and Class Members may hereafter discover facts in addition to or different from those that any of them now knows or believes to be true related to the subject matter of the Released Claims, but Lead Plaintiff shall expressly and each Class Member, upon the Effective Date, shall be deemed to have, and by operation of the Judgment shall have, fully, finally, and forever settled and released any and all Released Claims, known or unknown, suspected or unsuspected, contingent or non-contingent, disclosed or undisclosed, matured or unmatured, which now exist, or heretofore have existed, upon any theory of law or equity now existing or coming into existence in the future, including, but not limited to, conduct that is negligent, intentional, with or without malice, or a breach of any duty, law or rule, without regard to the subsequent discovery or existence of such different or additional facts. Similarly, the Released Parties may hereafter discover facts in addition to or different from those that any of them now knows or believes to be true related to the subject matter of the Settled Defendants' Claims, but each Defendant shall expressly and each of the Released Parties, upon the Effective Date, shall be deemed to have, and by operation of the Judgment shall have, fully, finally, and forever settled and released any and all Settled Defendants' Claims, known or unknown, suspected or unsuspected, contingent or non-contingent, disclosed or undisclosed, matured or unmatured, which now exist, or heretofore have existed, upon any theory of law or equity now existing or coming into existence in the future, including, but not limited to, conduct that is negligent, intentional, with or without malice, or a breach of any duty, law or rule, without regard to the subsequent discovery or existence of such different or additional facts. The Settling Parties acknowledge, and Lead Plaintiff, the Class Members, and the Released Parties shall be deemed by operation of the Judgment to have acknowledged, that the inclusion of "Unknown Claims" in the definition of Released Claims and Settled Defendants' Claims was separately bargained for and is a key element of the settlement of which these releases are a part.

If you remain a member of the Class, all of the Court's orders will apply to you and legally bind you. You will be bound by the releases whether or not you submit a Proof of Claim form and/or receive a payment under the Settlement.

EXCLUDING YOURSELF FROM THE SETTLEMENT

If you do not want a payment from this Settlement, but you want to keep any right you may have to sue or continue to sue the Defendants and the other Released Parties, on your own, about the Released Claims, then you must take steps to get out. This is called excluding yourself — or is sometimes referred to as "opting out" of the Class.

11. How do I get out of the proposed Settlement?

To exclude yourself from the Class, you must send a signed letter by mail stating that you request to be "excluded from the Class and do not wish to participate in the settlement in *In re CV Sciences, Inc. Securities Litigation*, Case No. 2:18-cv-01602-JAD-BNW (D. Nev.)." To be valid, your letter must state: (A) your name, address, telephone number, and signature; (B) the date, number, and dollar amount of all purchases, sales, or other dispositions of CV Sciences common stock during period from June 19, 2017 and through and including the close of trading on November 15, 2018. **The letter must also be accompanied by copies of broker confirmations or other documentation of your transactions in CV Sciences common stock.** You must mail your exclusion request such that it is received, not simply postmarked, no later than **July 1, 2022** to:

CV Sciences Securities Litigation
Claims Administrator
P.O. Box 2004
Chanhassen, MN 55317-2004

You cannot exclude yourself by telephone or e-mail. If you ask to be excluded, you will not get any payment from the Settlement, and you cannot object to the Settlement. You will not be legally bound by anything that happens in this lawsuit, and you may be able to sue (or continue to sue) the Defendants and the other Released Parties in the future.

12. If I do not exclude myself, can I sue the Defendants and the other Released Parties for the same thing later?

No. Unless you exclude yourself, you give up any rights to sue the Defendants and the other Released Parties for any and all Released Claims. If you have a pending lawsuit speak to your lawyer in that case immediately. You must exclude yourself from *this* Class to continue your own lawsuit. Remember, the exclusion deadline is **July 1, 2022**.

13. If I exclude myself, can I get money from the proposed Settlement?

No. If you exclude yourself, you will not get money from the proposed Settlement.

THE LAWYERS REPRESENTING THE CLASS

14. Do I have a lawyer in this case? How will the lawyers be paid?

The Court has appointed the law firm of Faruqi & Faruqi, LLP as Lead Counsel and Muckleroy Lunt, LLC as Liaison Counsel (collectively, “Plaintiff’s Counsel”) to represent Lead Plaintiff and all other Class Members in the Action.

You will not be separately charged for the fees or expenses of Plaintiff’s Counsel appointed by the Court. The Court will determine the amount of Plaintiff’s Counsel’s fees and expenses, which will be paid from the Settlement Fund. *See also* page 2 (“Statement of Attorneys’ Fees and Expenses Sought”). If you want to be represented by your own lawyer, you may hire one at your own expense.

OBJECTING TO THE SETTLEMENT

If you are a Class Member, you can tell the Court that you do not agree with the Settlement or some part of it. You can ask the Court to deny approval by filing an objection. You cannot ask the Court to order a different settlement; the Court can only approve or reject the Settlement. If the Court denies approval, no settlement payments will be sent out and the lawsuit will continue. If this is what you want to happen, you must object.

15. How do I tell the Court that I do not like the proposed Settlement?

If you are a Class Member you can object to the Settlement or any part of it, including but not limited to, the Plan of Allocation, or Lead Counsel’s application for attorneys’ fees and expenses, and give reasons why you think the Court should not approve it.

Any objection to the proposed Settlement must be in writing. If you file a timely written objection, you may, but are not required to, appear at the Final Approval Hearing, either in person or through your own attorney. If you appear through your own attorney, you are responsible for hiring and paying that attorney. All written objections and supporting papers must clearly identify:

- The case name and number (*In re CV Sciences, Inc. Securities Litigation*, Case No. 2:18-cv-01602-JAD-BNW (D. Nev.));
- Your full name, address, telephone number, and signature;
- Information sufficient to prove membership in the Class, including the number of shares of CV Sciences common stock purchased or sold during the Class Period, the dates and prices of each such purchase and sale, and broker confirmations or other documentation of your transactions;
- All grounds for the objection, accompanied by any legal support known to you or your counsel;
- The identity of all counsel who represent you, if any;
- A statement confirming whether you or any counsel representing you intend to personally appear and/or testify at the Final Approval Hearing; and
- A list of any persons who may be called to testify and copies of any exhibits you intend to introduce into evidence at the Final Approval Hearing in support of your objection.

Your objection and any supporting papers must be submitted to the Clerk of the United States District Court for the District of Nevada at the address set forth below as well as mailed by first-class mail to Lead Counsel and Defendants’ Counsel at the addresses set forth below:

Clerk's Office

Clerk of the Court
United States District Court
District of Nevada
Lloyd D George Courthouse
333 S. Las Vegas Blvd.
Las Vegas, NV 89101

Lead Counsel

Katherine M. Lenahan
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017

Defendants' Counsel

S. Todd Neal
Eric A. Plourde
Procopio, Cory, Hargreaves & Savitch LLP
525 B Street, Suite 2200
San Diego, CA 92101

Your objection and supporting papers must be received on or before **July 1, 2022**.

16. What is the difference between objecting and seeking exclusion?

Objecting is simply telling the Court that you do not like something about the proposed Settlement. You can object only if you stay in the Class. Excluding yourself is telling the Court that you do not want to be part of the Class. If you exclude yourself, you have no basis to object because the case no longer affects you.

THE COURT'S FINAL APPROVAL HEARING

17. When and where will the Court decide whether to approve the proposed settlement?

The Court will hold a Final Approval Hearing at 10:00 a.m. on July 22, 2022, at the District of Nevada, Lloyd D. George Court House, 333 S. Las Vegas Blvd., Las Vegas, NV 89101, Courtroom 6D. At this hearing the Court will consider whether the Settlement is fair, reasonable and adequate. The Court also will consider the proposed Plan of Allocation for the proceeds of the Settlement, and the application of Lead Counsel for attorneys' fees, payment of expenses, and an award to Lead Plaintiff for his costs and expenses. The Court will take into consideration any written objections filed in accordance with the instructions in question 15. The Court also may listen to people who have properly indicated, within the deadline identified above, an intention to speak at the hearing; but decisions regarding the conduct of the hearing will be made by the Court. *See* question 19 for more information about speaking at the hearing. After the hearing, the Court will decide whether to approve the Settlement, the proposed Plan of Allocation, and the other applications. We do not know how long these decisions will take.

You should be aware that the Court may change the date and time of the Final Approval Hearing without further notice to the Class. Thus, if you want to come to the hearing, you should check with Lead Counsel before coming to be sure that the date and/or time has not changed.

18. Do I have to come to the Final Approval Hearing?

No. Lead Counsel will answer questions the Court may have. But, you are welcome to come at your own expense. If you send an objection, you do not have to come to Court to talk about it. As long as you filed your written objection on time, the Court will consider it. You may also pay your own lawyer to attend, but it is not necessary. Class Members do not need to appear at the hearing or take any other action to indicate their approval.

19. May I speak at the Final Approval Hearing?

If you object to the Settlement, you may ask the Court for permission to speak at the Final Approval Hearing. To do so, you must include with your objection (see question 15 above) a statement stating that it is your "Notice of Intention to Appear in *In re CV Sciences, Inc. Securities Litigation*, Case No. 2:18-cv-01602-JAD-BNW (D. Nev.)." Persons who intend to object to the Settlement, the Plan of Allocation, or Lead Counsel's application for an award of attorneys' fees and expenses, and/or the application of an award of reasonable costs and expenses to Lead Plaintiff and who desire to present evidence at the Final Approval Hearing must include in their written objections the identity of any witnesses they may call to testify and exhibits they intend to introduce into evidence at the Final Approval Hearing. Unless otherwise ordered by the Court, you cannot speak at the hearing if you excluded yourself from the Class or if you have not provided written notice of your intention to speak at the Final Approval Hearing by the deadline identified, and in accordance with the procedures described in questions 15 and 17 above.

IF YOU DO NOTHING

20. What happens if I do nothing at all?

If you do nothing, you will get no money from the Settlement and you will be precluded from starting a lawsuit, continuing with a lawsuit, or being part of any other lawsuit against Defendants and the other Released Parties about the Released Claims in this case, ever again. To share in the Net Settlement Fund, you must submit a Proof of Claim form (*see* question 9). To start,

continue, or be a part of any other lawsuit against the Defendants and the other Released Parties about the Released Claims in this case you must exclude yourself from this Class (*see* question 11).

GETTING MORE INFORMATION

21. Are there more details about the proposed Settlement?

This Notice summarizes the proposed Settlement. For the precise terms and conditions of the Settlement, please see the Stipulation available at www.CVSciencesSecuritiesLitigation.com, or access the Court docket in this case, for a fee, through the Court's Public Access to Court Electronic Records (PACER) system at <https://ecf.nvd.uscourts.gov>.

PLEASE DO NOT TELEPHONE THE COURT OR THE COURT CLERK'S OFFICE
TO INQUIRE ABOUT THIS SETTLEMENT OR THE CLAIM PROCESS.

You can also get a copy of the Stipulation, and other documents related to the Settlement, as well as additional information about the Settlement by visiting the website dedicated to the Settlement, www.CVSciencesSecuritiesLitigation.com, where you will find answers to common questions about the Settlement, a Proof of Claim form, plus other information to help you determine whether you are a Class Member and whether you are eligible for a payment. You also can call the Claims Administrator toll free at 1-866-645-2347; write to *CV Sciences Securities Litigation*, Claims Administrator, P.O. Box 2004, Chanhassen, MN 55317-2004; or visit the website of Lead Counsel at www.faruqilaw.com.

PLAN OF ALLOCATION OF NET SETTLEMENT FUND AMONG CLASS MEMBERS

The Plan of Allocation is a matter separate and apart from the proposed Settlement, and any decision by the Court concerning the Plan of Allocation shall not affect the validity or finality of the proposed Settlement. The Court may approve the Plan of Allocation with or without modifications agreed to among the Settling Parties, or may approve another plan of allocation, without further notice to Class Members.

The objective of the Plan of Allocation is to equitably distribute the Net Settlement Fund among Authorized Claimants based on their respective alleged economic losses as a result of the alleged fraud, as opposed to losses caused by market- or industry-wide factors, or Company-specific factors unrelated to the alleged fraud. The Claims Administrator shall determine each Authorized Claimant's share of the Net Settlement Fund based upon the recognized loss formula (the "Recognized Loss") described below. A Recognized Loss will be calculated for each share of CV Sciences common stock purchased during the Class Period. The calculation of Recognized Loss will depend upon several factors, including when the shares of CV Sciences common stock were purchased during the Class Period, and for what amounts, and whether such shares were sold, and if sold, when they were sold, and for what amounts. The Recognized Loss is not intended to estimate the amount a Class Member might have been able to recover after a trial, nor to estimate the amount that will be paid to Authorized Claimants pursuant to the Settlement. The Recognized Loss is the basis upon which the Net Settlement Fund will be proportionately allocated to the Authorized Claimants. The Claims Administrator will use its best efforts to administer and distribute the Net Settlement Fund to the extent that it is equitably and economically feasible.

The Plan of Allocation was created with the assistance of a consulting damages expert, and reflects the unproven allegation that the price of CV Sciences common stock was artificially inflated throughout the Class Period. The estimated alleged artificial inflation in the price of CV Sciences common stock during the Class Period is \$2.47. The computation of the estimated alleged artificial inflation in the price of CV Sciences common stock during the Class Period is based on certain misrepresentations alleged by Lead Plaintiff and the price change in the stock, net of market- and industry-wide factors, in reaction to the public announcements that allegedly corrected the misrepresentations alleged by Lead Plaintiff.

Federal securities laws allow investors to recover for losses caused by disclosures which corrected the Defendants' previous misleading statements or omissions. Thus, in order to have been damaged by the alleged violations of the federal securities laws, CV Sciences common stock purchased during the Class Period must have been held during a period of time in which its price declined due to the disclosure of information which corrected an allegedly misleading statement or omission. Lead Plaintiff and Lead Counsel have determined that such price decline occurred during the trading day on August 20, 2018, at approximately 1:21 p.m. EST. Accordingly, if a share of CV Sciences common stock was sold prior to 1:21 p.m. EST on August 20, 2018, the Recognized Loss for that share is \$0.00, and any loss suffered is not compensable under the federal securities laws.³

The "90-day look back" provision of the Private Securities Litigation Reform Act of 1995 ("PSLRA") is incorporated into the calculation of the Recognized Loss. The limitations on the calculation of the Recognized Loss imposed by the PSLRA are applied such that losses on CV Sciences common stock purchased during the Class Period and held as of the close of the 90-day period subsequent to the Class Period (the "90-Day Lookback Period") cannot exceed the difference between the purchase price

paid for such stock and the average price of CV Sciences common stock during the 90-Day Lookback Period. The Recognized Loss on CV Sciences common stock purchased during the Class Period and sold during the 90-Day Lookback Period cannot exceed the difference between the purchase price paid for such stock and the rolling average price of CV Sciences common stock during the portion of the 90-Day Lookback Period elapsed as of the date of sale.

In the calculations below, all purchase and sale prices shall exclude any fees, taxes and commissions. If a Recognized Loss amount is calculated to be a negative number, that Recognized Loss shall be set to zero (\$0.00). Any transactions in CV Sciences common stock executed outside of regular trading hours for the U.S. financial markets shall be deemed to have occurred during the next regular trading session.

Calculation of Recognized Loss Per Share of CV Sciences Common Stock

For each share of CV Sciences common stock purchased during the Class Period (i.e., June 19, 2017 and August 20, 2018 at 1:21 p.m. EST, both dates inclusive), the Recognized Loss per share shall be calculated as follows:

- i. For each share of CV Sciences common stock that was sold prior to August 20, 2018, at 1:21 p.m. EST, the Recognized Loss per share is \$0.
- ii. For each share of CV Sciences common stock purchased during the Class Period that was subsequently sold during the period after August 20, 2018, at 1:21 p.m. EST, through November 15, 2018, inclusive (i.e., sold during the 90-Day Lookback Period), the Recognized Loss per share is *the lesser of*:
 - a. \$2.47;
 - b. The purchase price *minus* the sale price; or
 - c. The purchase price *minus* the “90-Day Lookback Value” on the date of sale provided in Table 1 below.
- iii. For each share of CV Sciences common stock purchased during the Class Period and still held as of the close of trading on November 15, 2018, the Recognized Loss per share is *the lesser of*:
 - a. \$2.47; or
 - b. The purchase price *minus* the average closing price of CV Sciences common stock during the 90-Day Lookback Period, which is \$5.00.

Sale / Disposition Date	90-Day Lookback Value	Sale / Disposition Date	90-Day Lookback Value	Sale / Disposition Date	90-Day Lookback Value
8/20/2018	\$4.21	9/19/2018	\$4.84	10/18/2018	\$4.93
8/21/2018	\$4.89	9/20/2018	\$4.86	10/19/2018	\$4.95
8/22/2018	\$5.64	9/21/2018	\$4.87	10/22/2018	\$4.95
8/23/2018	\$5.86	9/24/2018	\$4.87	10/23/2018	\$4.96
8/24/2018	\$5.94	9/25/2018	\$4.88	10/24/2018	\$4.96
8/27/2018	\$5.77	9/26/2018	\$4.89	10/25/2018	\$4.96
8/28/2018	\$5.54	9/27/2018	\$4.90	10/26/2018	\$4.96
8/29/2018	\$5.25	9/28/2018	\$4.90	10/29/2018	\$4.96
8/30/2018	\$5.12	10/1/2018	\$4.90	10/30/2018	\$4.96
8/31/2018	\$5.04	10/2/2018	\$4.89	10/31/2018	\$4.96
9/4/2018	\$4.98	10/3/2018	\$4.87	11/1/2018	\$4.97
9/5/2018	\$4.92	10/4/2018	\$4.85	11/2/2018	\$4.99
9/6/2018	\$4.83	10/5/2018	\$4.85	11/5/2018	\$5.01
9/7/2018	\$4.73	10/8/2018	\$4.85	11/6/2018	\$5.03
9/10/2018	\$4.71	10/9/2018	\$4.85	11/7/2018	\$5.04

3 Purchases of CV Sciences common stock on August 20, 2018, at a price at or above \$5.65 will be considered to have occurred before 1:21 p.m. EST that day. Sales of CV Sciences common stock on August 20, 2018, at a price at or below \$6.90 will be considered to have occurred after 1:21 p.m. EST.

9/11/2018	\$4.75	10/10/2018	\$4.85	11/8/2018	\$5.05
9/12/2018	\$4.77	10/11/2018	\$4.85	11/9/2018	\$5.05
9/13/2018	\$4.77	10/12/2018	\$4.86	11/12/2018	\$5.04
9/14/2018	\$4.77	10/15/2018	\$4.89	11/13/2018	\$5.03
9/17/2018	\$4.76	10/16/2018	\$4.90	11/14/2018	\$5.01
9/18/2018	\$4.81	10/17/2018	\$4.91	11/15/2018	\$5.00

INSTRUCTIONS APPLICABLE TO ALL CLAIMANTS

The payment you receive will reflect your proportionate share of the Net Settlement Fund. Such payment will depend on the number of securities that participate in the Settlement, and when those securities were purchased and sold. The number of claimants who send in claims varies widely from case to case.

A purchase or sale of CV Sciences common stock shall be deemed to have occurred on the “contract” or “trade” date as opposed to the “settlement” or “payment” date.

All purchase and sale prices shall exclude any fees, taxes, and commissions.

Acquisition by Gift, Inheritance, or Operation of Law: If a Class Member acquired CV Sciences common stock during the Class Period by way of gift, inheritance or operation of law, such a claim will be computed by using the date and price of the original purchase and not the date and price of transfer. To the extent that CV Sciences common stock were originally purchased prior to commencement of the Class Period, the Recognized Loss for that acquisition shall be deemed to be zero (\$0.00).

Notwithstanding any of the above, receipt of CV Sciences common stock during the Class Period in exchange for securities of any other corporation or entity shall not be deemed a purchase or sale of CV Sciences common stock.

The first-in-first-out (“FIFO”) basis will be applied to purchases and sales. Sales will be matched in chronological order, by trade date, first against CV Sciences common stock held as of the close of trading on June 18, 2017 (the last day before the Class Period begins) and then against the purchases of CV Sciences common stock during the Class Period beginning with the earliest purchase during the Class Period.

The date of covering a “short sale” is deemed to be the date of purchase of shares. The date of a “short sale” is deemed to be the date of sale of shares. In accordance with the Plan of Allocation, however, the Recognized Loss on “short sales” is zero. In the event that a claimant has an opening short position in CV Sciences common stock, the earliest Class Period purchases shall be matched against such opening short position and not be entitled to a recovery until that short position is fully covered.

Option contracts are not securities eligible to participate in the Settlement. With respect to CV Sciences common stock purchased or sold through the exercise of an option, the purchase/sale date of the stock shall be the exercise date of the option and the purchase/sale price of the stock shall be the closing price of CV Sciences common stock on the date of exercise. Any Recognized Loss arising from purchases of CV Sciences common stock acquired during the Class Period through the exercise of an option on CV Sciences common stock⁴ shall be computed as provided for other purchases of CV Sciences common stock in the Plan of Allocation.

Payment according to the Plan of Allocation will be deemed conclusive against all Authorized Claimants. A Recognized Loss will be calculated as defined herein and cannot be less than zero. The Claims Administrator shall allocate to each Authorized Claimant a pro rata share of the Net Settlement Fund based on his, her, or its total Recognized Loss as compared to the total Recognized Losses of all Authorized Claimants. No distribution will be made to Authorized Claimants who would otherwise receive a distribution of less than \$10.00. If the prorated payment to any Authorized Claimant calculates to less than \$10.00, it will not be included in the calculation (*i.e.*, that Authorized Claimant’s recognized claim will be deemed to be zero) and no distribution will be made to that Authorized Claimant. Any prorated amounts of less than \$10.00 will be included in the pool distributed to those whose prorated payments are \$10.00 or greater.

Class Members who do not submit an acceptable Proof of Claim form will not share in the Settlement proceeds. The settlement and the Judgment dismissing this Action with prejudice will nevertheless bind Class Members who do not submit a request for exclusion and/or submit an acceptable Proof of Claim form.

⁴ Including (1) purchases of CV Sciences common stock as the result of the exercise of a call option, and (2) purchases of CV Sciences common stock by the seller of a put option as a result of the buyer of such put option exercising that put option.

Please contact the Claims Administrator or Lead Counsel if you disagree with any determinations made by the Claims Administrator regarding your Proof of Claim. If you are unsatisfied with the determinations, you may ask the Court, which retains jurisdiction over all Class Members and the claims-administration process, to decide the issue by submitting a written request.

The Defendants, their respective counsel, and all other Released Parties will have no responsibility or liability whatsoever for the processing of Proof of Claim Forms, the investment of the Settlement Fund, the distribution of the Net Settlement Fund, the Plan of Allocation, or the payment of any claim. Lead Plaintiff and Plaintiff's Counsel, likewise, will have no liability for their reasonable efforts to execute, administer, and distribute the Settlement.

Distributions will be made to Authorized Claimants after all claims have been processed and after the Court has finally approved the Settlement. If any funds remain in the Net Settlement Fund by reason of uncashed distribution checks or otherwise, then, after the Claims Administrator has made reasonable and diligent efforts to have Class Members who are entitled to participate in the distribution of the Net Settlement Fund cash their distributions, any balance remaining in the Net Settlement Fund after a reasonable period of time after the date of the initial distribution shall, if feasible, be reallocated in an equitable and economic fashion among Authorized Claimants who negotiated the checks sent in the initial distribution and would receive a minimum of \$10.00. These redistributions shall be repeated, if economically feasible, until the balance remaining in the Net Settlement Fund is de minimis. Any de minimis balance that still remains in the Net Settlement Fund after such reallocation(s), which is not feasible or economical to reallocate among Authorized Claimants, shall be donated to Investor Protection Trust, a nationwide non-profit organization dedicated to providing investor education and advocacy.

SPECIAL NOTICE TO SECURITIES BROKERS AND OTHER NOMINEES

If you purchased shares of CV Sciences common stock in the United States or on the OTC between June 19, 2017 and August 20, 2018 at 1:21 p.m., inclusive, for the beneficial interest of a person or organization other than yourself, the Court has directed that, WITHIN TEN (10) CALENDAR DAYS OF YOUR RECEIPT OF THIS NOTICE, you either: (a) provide to the Claims Administrator the name, last known address, and last known email address of each person or organization for whom or which you purchased such CV Sciences common stock; or (b) request additional copies of this Notice and the Proof of Claim form and within ten (10) calendar days after receipt thereof mail the Notice and Proof of Claim form directly to the beneficial owners of that CV Sciences common stock.

You are entitled to reimbursement from the Settlement Fund of your reasonable expenses actually incurred in connection with the foregoing, including reimbursement of postage expense and the cost of ascertaining the names and addresses of beneficial owners. Those expenses will be paid upon request and submission of appropriate supporting documentation. All communications concerning the foregoing should be addressed to the Claims Administrator:

CV Sciences Securities Litigation
Claims Administrator
P.O. Box 2004
Chanhassen, MN 55317-2004
Phone: 1-866-645-2347
Email: Info@CVSciencesSecuritiesLitigation.com

Dated: March 30, 2022

CV Sciences Securities Litigation
Claims Administrator
P.O. Box 2004
Chanhassen, MN 55317-2004
www.CVSciencesSecuritiesLitigation.com

PROOF OF CLAIM AND RELEASE

I. GENERAL INSTRUCTIONS

1. To recover as a Member of the Class based on your claims in the action entitled *In re CV Sciences, Inc. Securities Litigation*, No. 2:18-cv-01602-JAD-BNW (D. Nev.) (the "Action"), you must complete and, on page 7 hereof, sign this Proof of Claim and Release form ("Claim Form"). If you fail to submit a timely and properly addressed (as set forth in paragraph 3 below) Claim Form along with the requested supporting documentation, your claims may be rejected and you may not receive any recovery from the Settlement Fund created in connection with the proposed settlement of the Action.¹
2. Submission of this Claim Form, however, does not assure that you will share in proceeds of the settlement of the Action.
3. YOU MUST MAIL YOUR COMPLETED AND SIGNED CLAIM FORM AND THE SUPPORTING DOCUMENTS REQUESTED HEREIN (OR SUBMIT THEM VIA EMAIL TO INFO@CVSCIENCESSECURITIESLITIGATION.COM SUCH THAT YOUR CLAIM IS POSTMARKED (OR SUBMITTED IF SENT VIA EMAIL) NO LATER THAN **JULY 15, 2022** TO THE CLAIMS ADMINISTRATOR, AT THE FOLLOWING ADDRESS:

CV Sciences Securities Litigation
Claims Administrator
P.O. Box 2004
Chanhassen, MN 55317-2004
Phone: 1-866-645-2347
Email: Info@CVSciencesSecuritiesLitigation.com

If you are NOT a Class Member (as defined in the Notice), DO NOT submit a Proof of Claim form. Also, NOTE THAT CLAIMS CALCULATING TO AN AWARD AMOUNT OF LESS THAN \$10.00 WILL **NOT** BE PAID.

4. If you are a Class Member and you did not timely request exclusion from the Class, you will be bound by the terms of any judgment entered in the Action, including the releases provided herein, WHETHER OR NOT YOU SUBMIT A CLAIM FORM.

II. CLAIMANT IDENTIFICATION

You are a Class Member if you purchased the common stock of CV Sciences, Inc. ("CV Sciences") in the United States or on the OTC between June 19, 2017 and August 20, 2018 at 1:21 p.m. EST, inclusive, and were allegedly damaged thereby. Excluded from the Class are: (a) Defendants; (b) the officers and directors of the Company at all relevant times; (c) members of any Defendant's immediate families; (d) any entity in which Defendants have or had a controlling interest or which is related to or affiliated with any of the Defendants; (e) the legal representatives, heirs, agents, successors or

¹ Capitalized terms not defined in this Claim Form have the meaning set forth in the Notice of Pendency and Proposed Settlement of Class Action ("Notice") that accompanies this Claim Form, and the Stipulation of Settlement, dated January 31, 2022 (the "Stipulation"), which can be obtained at www.CVSciencesSecuritiesLitigation.com.

assigns of such excluded Persons; (f) Defendants' liability insurance carriers and any affiliates or subsidiaries thereof; (g) those who purchased CV Sciences common stock on foreign exchanges, in accordance with the United States Supreme Court's decision in *Morrison v. Nat'l Australia Bank Ltd.*, 561 U.S. 247, 267 (2010) ("[I]t is in our view only transactions in securities listed on domestic exchanges, and domestic transactions in other securities, to which §10(b) applies."); and (h) any Persons who exclude themselves by submitting a request for exclusion that is accepted by the Court.

If you purchased CV Sciences common stock and held the certificate(s) in your name, you are the beneficial purchaser as well as the record purchaser. If, however, the certificate(s) was registered in the name of a third party, such as a nominee or brokerage firm, you are the beneficial purchaser, and the third party is the record purchaser.

Use Part I of this form entitled "Claimant Information" to identify yourself and each owner of record ("nominee") if different from the beneficial owner of CV Sciences common stock that forms the basis of this claim. THIS CLAIM MUST BE FILED BY THE ACTUAL BENEFICIAL PURCHASER(S), OR THE LEGAL REPRESENTATIVE OF SUCH PURCHASER(S) OF THE CV SCIENCES COMMON STOCK UPON WHICH THIS CLAIM IS BASED.

All joint purchasers must sign this Claim Form. Executors, administrators, guardians, conservators, and trustees must complete and sign this Claim Form on behalf of persons represented by them and their authority must accompany this claim and their titles or capacities must be stated. The Social Security (or taxpayer identification) number and telephone number of the beneficial owner may be used in verifying the claim. Failure to provide the foregoing information could delay verification of your claim or result in rejection of the claim.

If you are acting in a representative capacity on behalf of a Class Member (for example, as an executor, administrator, trustee, or other representative), you must submit evidence of your current authority to act on behalf of that Class Member. Such evidence would include, for example, letters testamentary, letters of administration, or a copy of the trust documents.

NOTICE REGARDING ELECTRONIC FILES: Certain claimants with large numbers of transactions may request, or may be requested, to submit information regarding their transactions in electronic files. All claimants MUST submit a manually signed paper Claim Form listing all their transactions whether or not they also submit electronic copies. If you wish to file your claim electronically, you must contact the Claims Administrator at Info@CVSciencesSecuritiesLitigation.com or visit their website at www.CVSciencesSecuritiesLitigation.com to obtain the required file layout. No electronic files will be considered to have been properly submitted unless the Claims Administrator issues to the Claimant a written acknowledgment of receipt and acceptance of electronically submitted data.

III. CLAIM FORM

Use Part II of this form entitled "Schedule of Transactions in CV Sciences Common Stock," to supply all required details of your transaction(s) in CV Sciences common stock. If you need more space or additional schedules, attach separate sheets giving all of the required information in substantially the same form. Sign and print or type your name on each additional sheet.

On the schedules, provide all the requested information with respect to (1) all of your purchases and sales of CV Sciences common stock that took place between June 19, 2017 and November 15, 2018, inclusive; (2) the number of shares of common stock that you held at the opening of trading on June 19, 2017; and (3) the number of shares of common stock that you held at the close of trading on November 15, 2018. Failure to report all such transactions may result in the rejection of your claim.

List each transaction separately and in chronological order, by trade date, beginning with the earliest. You must accurately provide the month, day, and year of each transaction you list.

The date of covering a "short sale" is deemed to be the date of purchase of CV Sciences common stock. The date of a "short sale" is deemed to be the date of sale of CV Sciences common stock.

For each transaction, you must provide, together with this Claim Form, copies of stockbroker confirmations slips, stockbroker statements, or other documents adequately evidencing your transactions in CV Sciences common stock. If any such documents are not in your possession, please obtain a copy or equivalent documents from your broker because these documents are necessary to prove and process your claim. Failure to provide this documentation could delay verification of your claim or result in rejection of your claim.

CV SCIENCES, INC. SECURITIES LITIGATION

PART I. CLAIMANT INFORMATION

Please Type or Print

Beneficial Owner's Name (as it appears on your brokerage statement)

First Name

M.I.

Last Name

Joint Beneficial Owner's Name (as it appears on your brokerage statement)

First Name

M.I.

Last Name

Entity Name (if claimant is not an individual)

Address 1 (street name and number)

Address 2 (apartment, unit, or box number)

City

State/Province ZIP Code

Foreign Postal Code (if applicable)

Foreign Country (if applicable)

Day Phone

Evening Phone

Email Address

Social Security Number (for individuals)

or

Taxpayer Identification Number (for estates, trusts, corporations, etc.)

PART II. SCHEDULE OF TRANSACTIONS IN CV SCIENCES COMMON STOCK

BEGINNING HOLDINGS

A. State the total number of CV Sciences common stock owned at the opening of trading on June 19, 2017, long or short. If none, write "zero" or "0"; if other than zero, must be documented.

Check Here If Documentation is Enclosed

--	--	--	--	--	--	--	--

PURCHASES

B. Separately list each and every share you purchased of CV Sciences common stock during the period from **June 19, 2017 through November 15, 2018, inclusive**, and provide the following information (*must be documented*):²

Trade Date (List Chronologically)			Number of Shares Purchased	Purchase Price Per Share		Total Cost (Excluding Commissions, Taxes and Fees)		Check Here If Documentation is Enclosed
M	M	Y				\$		

SALES

C. Separately list each and every sale of CV Sciences common stock during the period between **June 19, 2017 and November 15, 2018, inclusive**, and provide the following information (*must be documented*):

Trade Date (List Chronologically)			Number of Shares Sold	Sale Price Per Share		Total Cost (Excluding Commissions, Taxes and Fees)		Check Here If Documentation is Enclosed
M	M	Y				\$		

ENDING HOLDINGS

D. State the total number of shares of CV Sciences common stock owned at the close of trading on November 15, 2018, long or short. If none, write "zero" or "0"; if other than zero, must be documented.

Check Here If Documentation is Enclosed

--	--	--	--	--	--	--	--

If additional space is needed, attach separate, numbered sheets, giving all required information, substantially in the same format, and print your name and Social Security or Taxpayer Identification Number at the top of each sheet.

NOTE THAT CLAIMS CALCULATING TO AN AWARD AMOUNT LESS THAN \$10.00 WILL NOT BE PAID.

² Please note: Information requested with respect to your purchase of CV Sciences common stock after 1:21 p.m. EST on August 20, 2018 through and including the close of trading on November 15, 2018 (Section C) is needed in order to calculate your claim; purchases during this period, however, are not eligible under the settlement.

**YOU MUST READ AND SIGN THE RELEASE BELOW.
FAILURE TO SIGN THE RELEASE MAY RESULT IN A DELAY
IN PROCESSING OR THE REJECTION OF YOUR CLAIM.**

PART III. SUBSTITUTE FORM W-9

Request for Taxpayer Identification Number:

Enter taxpayer identification number below for the Beneficial Owner(s). For most individuals, this is your Social Security Number. The Internal Revenue Service (“I.R.S.”) requires such taxpayer identification number. If you fail to provide this information, your claim may be rejected.

Social Security Number (*for individuals*)

Tax Payer Identification Number (*for estates, trusts, corporations, etc.*)

□□□□—□□—□□□□

OR

□□—□□□□□□□□

PART IV. SUBMISSION TO JURISDICTION OF COURT AND ACKNOWLEDGMENTS

I (We) submit this Claim Form under the terms of the Stipulation described in the Notice. I (We) also submit to the jurisdiction of the Court, with respect to my (our) claim as a Class Member and for purposes of enforcing the releases set forth herein. I (We) further acknowledge that I am (we are) bound by and subject to the terms of any judgment that may be entered in the Action. I (We) agree to furnish additional information to the Claims Administrator to support this claim if requested to do so. I (We) have not submitted any other claim covering the same purchases, acquisitions, or sales of CV Sciences common stock during the relevant period and know of no other person having done so on my (our behalf).

PART V. RELEASES

1. I (We) hereby acknowledge full and complete satisfaction of, and do hereby fully, finally, and forever settle, release, and discharge from the Released Claims each and all of the Released Parties as provided in the Stipulation of Settlement.
2. “Released Claims” means all known or unknown claims that both: (a) arise out of, are based upon, or relate in any way to any of the allegations, acts, transactions, facts, events, matters, occurrences, statements, representations, misrepresentations or omissions involved, set forth, alleged or referred to, in this Action, or which could have been alleged in this Action; and (b) arise out of, are based upon, or relate in any way to the purchase of the common stock of CV Sciences in the United States or on the OTC during the Class Period. Released Claims do not include (i) any claims relating to the enforcement of the settlement or (ii) any Excluded Claims. “Released Claims” includes “Unknown Claims” as defined below.
3. “Excluded Claims” means the (i) derivative claims brought on behalf of CV Sciences, including *Depoti v. Dowling, et al.*, Docket No. A-18-782513-C (Nev. Dist. Ct. Oct. 10, 2018); *Francis v. Mona, Jr., et al.*, No. 2:18-cv-02284 (D. Nev. Nov. 30, 2018); *Tarangelo v. Mona, Jr., et al.*, Docket No. A-19-789153-B (Nev. Dist. Ct. Feb. 11, 2019); *Radcliffe v. Joseph Dowling, et al.*, Docket No. A-19-794377-B (Nev. Dist. Ct. May 7, 2019); *Berry v. Dowling, et al.*, Docket No. 3:20-cv-01072 (S.D. Cal. Jun. 11, 2020); *Menna v. Dowling, et al.*, Docket No. 37-2021-00019613-CU-SL-CTL (Cal. Super. Ct. Apr. 22, 2021), and any similar claims that may be filed or consolidated therewith; or (ii) any claims relating to the enforcement of the settlement.
4. “Related Parties” means each of Defendants’ predecessors, successors, parent corporations, sister corporations, subsidiaries, affiliates, assigns, assignors, divisions, joint ventures, heirs, legatees, executors, administrators, estates, receivers and trustees, settlors, beneficiaries, officers, directors, shareholders, employees, agents, consultants, contractors, auditors, partners, insurers, reinsurers, representatives, attorneys, legal representatives, and all persons acting by, through, under or in concert with them or any of them.
5. “Released Parties” means each and all of the Defendants and their respective Related Parties.
6. “Settled Defendants’ Claims” means all known or unknown claims, demands, losses, rights, and causes of action of any nature whatsoever, that have been or could have been asserted in the Action or any forum by the Released Parties or any of them against Lead Plaintiff, Class Members, and Plaintiff’s Counsel, which arise out of or relate in any way to the institution, prosecution, assertion, settlement, or resolution of the Action (except for claims to enforce the settlement). “Settled Defendants’ Claims” includes “Unknown Claims” as defined below.

7. "Unknown Claims" means: (a) any and all Released Claims that Lead Plaintiff or any Class Member does not know or suspect to exist in his, her, their or its favor at the time of the release of the Released Parties which, if known by him, her, them or it, might have affected his, her, their or its settlement with and release of the Released Parties, or might have affected his, her, their or its decision(s) with respect to the settlement, including the decision to object to the terms of the settlement or to exclude himself, herself, themselves or itself from the settlement Class; and (b) any Settled Defendants' Claims that any Released Party does not know or suspect to exist in his, her, their or its favor at the time of the release of the Lead Plaintiff, Class Members, and Plaintiff's Counsel, which, if known by him, her, them or it, might have affected his, her, their or its decision(s) with respect to the settlement with and release of the Lead Plaintiff, Class Members, and Plaintiff's Counsel, or might have affected his, her, their or its decision(s) with respect to the settlement. With respect to any and all Released Claims and Settled Defendants' Claims, the Settling Parties stipulate and agree that, upon the Effective Date, Lead Plaintiff and Defendants shall expressly waive, and each of the Class Members shall be deemed to have, and by operation of the Judgment shall have, expressly waived any and all provisions, rights, and benefits conferred by California Civil Code §1542 and any law of any state or territory of the United States, or principle of common law, which is similar, comparable, or equivalent to California Civil Code §1542, which provides:

A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.

Lead Plaintiff and Class Members may hereafter discover facts in addition to or different from those that any of them now knows or believes to be true related to the subject matter of the Released Claims, but Lead Plaintiff shall expressly, and each Class Member, upon the Effective Date, shall be deemed to have, and by operation of the Judgment shall have, fully, finally, and forever settled and released any and all Released Claims, known or unknown, suspected or unsuspected, contingent or non-contingent, disclosed or undisclosed, matured or unmatured, which now exist, or heretofore have existed upon any theory of law or equity now existing or coming into existence in the future, including, but not limited to, conduct that is negligent, intentional, with or without malice, or a breach of any duty, law or rule, without regard to the subsequent discovery or existence of such different or additional facts. Similarly, the Released Parties may hereafter discover facts in addition to or different from those that any of them now knows or believes to be true related to the subject matter of the Settled Defendants' Claims, but each Defendant shall expressly and each of the Released Parties, upon the Effective Date, shall be deemed to have, and by operation of the Judgment shall have, fully, finally, and forever settled and released any and all Settled Defendants' Claims, known or unknown, suspected or unsuspected, contingent or non-contingent, disclosed or undisclosed, matured or unmatured, which now exist, or heretofore have existed upon any theory of law or equity now existing or coming into existence in the future, including, but not limited to, conduct that is negligent, intentional, with or without malice, or a breach of any duty, law or rule, without regard to the subsequent discovery or existence of such different or additional facts. The Settling Parties acknowledge, and Lead Plaintiff, the Class Members, and the Released Parties shall be deemed by operation of the Judgment to have acknowledged, that the inclusion of "Unknown Claims" in the definition of Released Claims and Settled Defendants' Claims was separately bargained for and is a key element of the settlement of which these releases are a part.

8. These releases shall be of no force or effect unless and until the Court approves the Stipulation and the settlement becomes effective on the Effective Date.
9. I (We) hereby warrant and represent that I (we) have not assigned or transferred or purported to assign or transfer, voluntarily or involuntarily, any claim or matter released pursuant to this release or any other part or portion thereof.
10. I (We) hereby warrant and represent that I (we) have included all the information requested (including supporting documentation) about all of my (our) purchases and sales of CV Sciences common stock between June 19, 2017 and November 15, 2018, inclusive, and the number of shares of CV Sciences common stock held by me (us) at the beginning of trading on June 19, 2017 and the close of trading on November 15, 2018. I (we) agree to furnish additional information to the Claims Administrator to support this claim if requested to do so.
11. I (We) certify that I am (we are) NOT subject to backup withholding under the provisions of Section 3406 (a)(1)(c) of the Internal Revenue Code because: (a) I am (we are) exempt from backup withholding, or (b) I (we) have not been notified by the I.R.S. that I am (we are) subject to backup withholding as a result of a failure to report all interest or dividends, or (c) the I.R.S. has notified me (us) that I am (we are) no longer subject to backup withholding.

NOTE: If you have been notified by the I.R.S. that you are subject to backup withholding, please strike out the language that you are not subject to backup withholding in the certification above.

I (WE) DECLARE UNDER PENALTY OF PERJURY UNDER THE LAWS OF THE UNITED STATES OF AMERICA THAT ALL OF THE INFORMATION I (WE) PROVIDED ON THIS CLAIM FORM IS TRUE, CORRECT AND COMPLETE.

Signature of Claimant

Signature of Joint Claimant, if any

(Type or print your name here)

(Type or print your name here)

Capacity of person(s) signing (e.g. Beneficial Purchaser, Executor or Administrator)

Capacity of person(s) signing (e.g. beneficial Purchaser, Executor or Administrator)

Check here if proof of authority to file is enclosed.
(See explanation in II. Claimant Identification)

Check here if proof of authority to file is enclosed.
(See explanation in II. Claimant Identification)

Executed this _____ day of _____.
(Month/Year)

THE CLAIM FORM AND SUPPORTING DOCUMENTATION MUST BE POSTMARKED (OR SUBMITTED IF SENT VIA EMAIL TO INFO@CVSCIENCESSECURITIESLITIGATION.COM) ON OR BEFORE JULY 15, 2022 ADDRESSED TO THE CLAIMS ADMINISTRATOR AS FOLLOWS:

CV Sciences Securities Litigation
Claims Administrator
P.O. Box 2004
Chanhassen, MN 55317-2004
Phone: 1-866-645-2347
Email: Info@CVSciencesSecuritiesLitigation.com

A Claim Form received by the Claims Administrator shall be deemed to have been submitted when posted, if mailed by **July 15, 2022** and if a postmark is indicated on the envelope and it is mailed and addressed in accordance with the above instructions. In all other cases, a Claim Form shall be deemed to have been submitted when actually received by the Claims Administrator.

You should be aware that it will take a significant amount of time to process fully all of the Claim Forms and to administer the settlement. This work will be completed as promptly as time permits, given the need to investigate and tabulate each Proof of Claim. Please notify the Claims Administrator of any change of address.

REMINDER CHECKLIST:

- Please be sure to sign this Claim Form on page 7. If this Claim Form is submitted on behalf of joint claimants, then both claimants must sign.
- Please remember to attach supporting documents. Do NOT send originals of stock certificates. Keep copies of everything you submit.
- Do NOT use highlighter on the Claim Form or any supporting documents.
- If you move after submitting this Claim Form, please notify the Claims Administrator of the change in your address.

EXHIBIT B

INVESTOR'S BUSINESS DAILYSM

Affidavit of Publication

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

Name of Publication: IBD Weekly
Address: 12655 Beatrice Street
City, State, Zip: Los Angeles, CA 90066
Phone #: 310.448.6700
State of: California
County of: Los Angeles


I, Shaun Shen for the publisher of IBD Weekly, published in the city of Los Angeles, state of California, county of Los Angeles hereby certify that the attached notice(s) for CV SCIENCES, INC. was printed in said publication on the following date(s):


APRIL 11, 2022

State of California

County of Los Angeles

Subscribed and sworn to (or affirmed) before me on this 11th day of April, 2022, by

, proved to me on the basis of satisfactory evidence to be the person(s) who appeared before me.

Signature  (Seal)




EXHIBIT C

Faruqi & Faruqi, LLP Announces Proposed Settlement Of In Re CV Sciences, Inc. Securities Litigation

NEWS PROVIDED BY
Faruqi & Faruqi, LLP →
Apr 11, 2022, 10:00 ET

NEW YORK, April 11, 2022 /PRNewswire/ --

**UNITED STATES DISTRICT COURT
DISTRICT OF NEVADA**

In re: CV SCIENCES, INC. SECURITIES LITIGATION	Case No. 2:18-cv-01602-JAD-BNW
This Document Relates to: All Actions	

SUMMARY NOTICE OF PROPOSED SETTLEMENT OF CLASS ACTION

TO: ALL PERSONS WHO PURCHASED THE COMMON STOCK OF CV SCIENCES, INC. ("CV SCIENCES") IN THE UNITED STATES OR ON THE OTC BETWEEN JUNE 19, 2017 AND AUGUST 20, 2018 AT 1:21 P.M. EST, INCLUSIVE, AND WERE DAMAGED THEREBY ("CLASS").

YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the District of Nevada, that Lead Plaintiff Richard Ina, Trustee for the Ina Family Trust ("Lead Plaintiff"), on behalf of himself and each member of the Class, and defendants CV Sciences, Michael Mona, Jr., Joseph D. Dowling, and Michael Mona, III, have reached a proposed settlement of the above-captioned action ("Action") in the amount of \$712,500 that, if approved, will resolve the Action in its entirety (the "Settlement").

A hearing will be held on July 22, 2022 at 10:00 a.m., at the Lloyd D. George Court House, 333 S. Las Vegas

Blvd., Las Vegas, NV 89101, Courtroom 6D for the purpose of determining: (1) whether the proposed Settlement as set forth in the Stipulation of Settlement dated January 31, 2022 ("Stipulation") of the Action is fair, reasonable, and adequate; (2) whether a Judgment should be entered by the Court dismissing the Action with prejudice; (3) whether the Plan of Allocation for distribution of the settlement funds available for distribution is fair, reasonable, and adequate and should be approved; and (4) whether the application of Lead Counsel for the payment of attorneys' fees in the amount of 25% of the Settlement Fund, reimbursement of Lead Counsel's expenses up to \$50,000, and an award to Lead Plaintiff for his reasonable costs and expenses up to \$12,000 should be approved.

IF YOU PURCHASED THE COMMON STOCK OF CV SCIENCES IN THE UNITED STATES OR ON THE OTC BETWEEN JUNE 19, 2017 AND AUGUST 20, 2018 AT 1:21 P.M EST, INCLUSIVE, YOUR RIGHTS MAY BE AFFECTED BY THE SETTLEMENT OF THIS LITIGATION. You may obtain copies of a detailed Notice of Pendency and Settlement of Class Action ("Notice") and Proof of Claim and Release form ("Claim Form") by writing to *CV Sciences Securities Litigation*, Claims Administrator, P.O. Box 2004, Chanhassen, MN 55317-2004, visiting the website www.CVSciencesSecuritiesLitigation.com, e-mailing the Claims Administrator at Info@CVSciencesSecuritiesLitigation.com, or calling the Claims Administrator toll free at 1-866-645-2347. Inquiries other than requests for the above-referenced documents may also be made to Lead Counsel:

Katherine M. Lenahan
FARUQI & FARUQI, LLP
685 Third Avenue
26th Floor
New York, NY 10017

If you are a Class Member, in order to share in the distribution of the Settlement Fund, you must submit a Claim Form postmarked or submitted electronically no later than **JULY 15, 2022**, establishing that you are entitled to recovery. NOTE THAT NO CLAIMS LESS THAN \$10.00 WILL BE PROCESSED OR PAID. Your failure to timely submit your Claim Form will subject your claim to possible rejection and may preclude you from receiving any of the recovery in connection with the settlement of this Action.

To exclude yourself from the Class, you must submit a written request for exclusion in accordance with the instructions set forth in the Notice such that it is received no later than **JULY 1, 2022**. All Class Members who have not requested exclusion from the Class will be bound by the Settlement entered in the Action even if they do not submit a timely Claim Form.

Any objection to the Settlement, the Plan of Allocation of settlement proceeds, or the fee and expense

application must be received by each of the addresses indicated in the Notice on or before **JULY 1, 2022**.

PLEASE DO NOT CONTACT THE COURT OR THE CLERK'S OFFICE REGARDING THIS NOTICE, THIS SETTLEMENT, OR THIS CLAIMS PROCESS. If you have any questions about the Settlement, you may contact Lead Counsel at the address listed above.

SOURCE Faruqi & Faruqi, LLP

EXHIBIT D

Date: April 18, 2022

To: Claims Administrator

This letter is to declare that we wish to be excluded from the Class Action and do not wish to participate in the settlement in:

In re CV Sciences, Inc. Securities Litigation, Case No. 2:18-cv-01602-JAD-BNW (D. Nev.)

(A)

Jesse Miller

Christine Moondancer



(B)

08/28/2018 Bought 360 CVSI @ 4.12



08/29/2018 Bought 130 CVSI @ 3.80

Two handwritten signatures in black ink. The top signature is more stylized and angular, while the bottom signature is more cursive and includes a large loop at the end.

4/18/22

4/18/22

Miller/Mondancer



CONFIDENTIAL

CV Sciences Securities Litigation
Claims Administrator
P.O. Box 2007
Chanhassen, MN 55317-2007